Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 11491133 Heteroaryl-isochroman compounds and uses thereof
Overview
Structured Data
Issues
Contributors
Activity
All edits
Edits on 17 Apr, 2024
"update inverses"
Golden AI
edited on 17 Apr, 2024
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11958862 Compounds and compositions and uses thereof
0
Edits on 16 Oct, 2023
"Add patent inventor(s)"
Golden AI
edited on 16 Oct, 2023
Edits made to:
Infobox
(
+5
properties)
Infobox
Patent Inventor Names
Carrie A. Bowen
0
Douglas F. Burdi
0
Lee W. Herman
0
Linghong Xie
0
Michele L. R. Heffernan
0
Edits on 9 Nov, 2022
"Created via: Entity Importer"
Golden AI
created this topic on 9 Nov, 2022
Edits made to:
Infobox
(
+13
properties)
US Patent 11491133 Heteroaryl-isochroman compounds and uses thereof
Infobox
Is a
Patent
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
11491133
0
Date of Patent
November 8, 2022
0
Patent Application Number
16991771
0
Date Filed
August 12, 2020
0
Patent Citations
US Patent 10085968 Multicyclic compounds and methods of use thereof
0
US Patent 10189825 Heteroaryl compounds and methods of use thereof
0
US Patent 10196403 Compounds and compositions and uses thereof
0
US Patent 10336732 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
0
US Patent 10556890 Heteroaryl compounds and methods of use thereof
0
Patent Primary Examiner
Susanna Moore
0
CPC Code
C07D 311/76
0
Find more entities like US Patent 11491133 Heteroaryl-isochroman compounds and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
SUBSCRIBE